3 results
See protocol page 23This study is designed to assess the usability and functionality of the Reveal LINQ system. Data from the first 30 patients, with 30 days of follow-up, will be used to assess sensing performance and wireless capabilities of theā¦
Primary objective: To determine the safety of once daily inhalation of the recommended daily dose of tobramycin with the AkitaĀ® and the PARI-LCĀ® Plus nebulizer in patients with CF. Systemic absorption can be used as surrogate parameter for safety.ā¦
To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.